Comments
MSN Group’s (MSN) marketing partner, Breckenridge Pharmaceutical, has received final approval for its Abbreviated New Drug Application (ANDA) for Asenapine Sublingual Tablets, in 2.5 mg and 10 mg strengths, a generic for Saphris, with the US Food and Drug Administration.
“These strengths will be launched immediately. Additionally, the 5 mg strength received tentative approval,” Hyderabad-based MSN said in a release.
This product was developed in collaboration with Breckenridge Pharmaceutical for the US Market.
They are indicated for the treatment of patients suffering from schizophrenia and bipolar disorder.
As per industry sales data, Asenapine had annual sales of $239 million during the 12 months ending September 2020.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.